Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yosuke Aoyama
Observed name:
Y. Aoyama
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Toranomon Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0003-0081-9115
Observed ORCID:
0000-0003-0081-9115
OpenAlex ID:
A5036072503
Efficacy of Telemedicine Using Videoconferencing Systems in Outpatient Care for Patients With Cancer: A Systematic Review and Meta-Analysis
2022
·
Yasuaki Uemoto
, Taro Yamanaka
, et al.
·
JCO Clinical Cancer Informatics
·
21
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
2024
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Breast Cancer
·
11
Primary bronchial schwannoma: A case report
2022
·
Yosuke Aoyama
, Atsushi Miyamoto
, et al.
·
Medicine
·
11
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
2022
·
Yukinori Ozaki
, Yosuke Aoyama
, et al.
·
BMC Cancer
·
9
PDF
Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
2024
·
Takayuki Kobayashi
, Meiko Nishimura
, et al.
·
BMC Cancer
·
5
PDF
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale
2023
·
Yosuke Aoyama
, Eri Hoshino
, et al.
·
Breast Cancer
·
3
Risk factors and long-term prognostic impact of trastuzumab deruxtecan-related interstitial lung disease in metastatic breast cancer.
2026
·
Takayuki Kobayashi
, Meiko Nishimura
, et al.
·
Journal of Clinical Oncology
·
1
Cytokine-mediated hypersensitivity reactions to carboplatin in early triple-negative breast cancer with neoadjuvant pembrolizumab plus chemotherapy.
2025
·
Masahiro Kuno
, Yosuke Aoyama
, et al.
·
Journal of Clinical Oncology
·
1
PDF
[Malignant Spinal Cord Compression].
2020
·
Yosuke Aoyama
, Chihiro Kondoh
, et al.
·
PubMed
·
1
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
2026
·
Yukinori Ozaki
, Emi Taniguchi
, et al.
·
The Breast
S-1 versus capecitabine as first-line chemotherapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in the era of cyclin-dependent kinase 4/6 inhibitors: a retrospective cohort study
2026
·
Takayuki Kobayashi
, Meiko Nishimura
, et al.
·
BMC Cancer
Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
BMC Cancer
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Breast Cancer
PDF
Sex differences in chemotherapy-induced alopecia distress using the Japanese version of the Chemotherapy-Induced Alopecia Distress Scale
2026
·
Hiroki Okumura
, Shuko Soma
, et al.
·
Supportive Care in Cancer
A Case of Transient ACTH and Cortisol Suppression Caused by Dexamethasone Mouthwash during Immune Checkpoint Inhibitor Treatment
2026
·
Yosuke Aoyama
, Yurie Haruyama
, et al.
·
Internal Medicine
PDF
Prospective study of a novel portable scalp-cooling cap for prevention of chemotherapy-induced alopecia.
2026
·
Yosuke Aoyama
, Takehiko Sakai
, et al.
·
Journal of Clinical Oncology
Survival, fertility preservation, and pregnancy after treatment in young patients with BRCA-associated triple-negative breast cancer.
2026
·
Akemi Kataoka
, Meiko Nishimura
, et al.
·
Journal of Clinical Oncology
Efficacy of datopotamab deruxtecan after trastuzumab deruxtecan in metastatic hormone receptor–positive HER2-negative breast cancer: A real-world study.
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Journal of Clinical Oncology
PDF
Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial
2026
·
Yosuke Aoyama
, Kosuke Kashiwabara
, et al.
·
Breast Cancer
Real-world pathological outcomes after neoadjuvant chemotherapy with subcutaneous versus intravenous pertuzumab and trastuzumab in HER2-positive early breast cancer
2026
·
Haruka Ozaki
, Jun Masuda
, et al.
·
SSRN Electronic Journal
PDF
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort
2025
·
Yuka Morita
, Koichi Takeda
, et al.
·
Rheumatology
86MO Minimal important differences in the EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: Results from a randomized trial
2025
·
Y. Aoyama
, K. Kashiwabara
, et al.
·
Annals of Oncology
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy
2025
·
Meiko Nishimura
, Takayuki Kobayashi
, et al.
·
Breast Disease
O4-4 Linguistic validation of a Japanese version of the Chemotherapy-induced Alopecia Distress Scale
2022
·
Yosuke Aoyama
, Yuichiro Kikawa
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
24
Citation count:
63
H-index:
5
I10-index:
3
Year
Topic
Type